drugset
drugset / Trial / NCT00876317

Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder

NCT00876317 ↗

Phase 3 Terminated 45 enrolled Clinica Virgen Milagrosa Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety two oral doses of etoricoxib (60 mg and 90 mg) daily in acute soft tissue rheumatism affecting the shoulder.

Timeline

Start
2009-11
Primary completion
2010-11
Completion
2010-12

Outcome

Outcome not reported

Stopped: “Change in current areas of research interest of the collaborator”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoricoxib Small molecule 60 mg Oral
Comparator Etoricoxib Small molecule 90 mg Oral

Indications

tenosynovitis